Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Doc Ophthalmol ; 147(1): 71-75, 2023 08.
Article in English | MEDLINE | ID: mdl-37369909

ABSTRACT

BACKGROUND: Pseudophakic cystoid macular edema (PCME) is the most common cause of visual acuity deterioration after uncomplicated cataract surgery. There is no consensus regarding how to manage recurrent or refractory cases. REPORT: A 54-year-old woman complained of decreased vision and central metamorphopsia in the right eye (OD) 3 months after uneventful cataract surgery. Visual acuity was 0.3 logMAR (20/40) OD and 0.1 logMAR (20/25) OS. Reduced macular brightness was seen OD on funduscopy associated with increased macular thickness on optical coherence tomography (OCT). Pseudophakic cystoid macular edema (PCME) was diagnosed, and treatment with oral acetazolamide was tried without success. The patient underwent a single intravitreal injection of an acetazolamide implant (260 µg) OD as off-label treatment. Four weeks following the injection, she reported complete resolution of her metamorphopsia and visual loss OD. Four months later, her visual acuity was 0.0 logMAR (20/20) in OD and 0.1 logMAR (20/25) in OS. The patient reported no discomfort after the injection procedure. Laboratory and ophthalmologic tests did not identify any adverse effects of the medication. CONCLUSION: We show that PCME refractory to conventional treatment improved after intravitreal acetazolamide implant injection. Further investigation is warranted to confirm these preliminary findings.


Subject(s)
Cataract Extraction , Cataract , Macular Edema , Humans , Female , Middle Aged , Macular Edema/diagnosis , Macular Edema/drug therapy , Macular Edema/etiology , Acetazolamide/therapeutic use , Electroretinography , Cataract Extraction/adverse effects , Tomography, Optical Coherence , Intravitreal Injections , Cataract/complications , Cataract/drug therapy
2.
J Control Release ; 350: 228-243, 2022 10.
Article in English | MEDLINE | ID: mdl-35995297

ABSTRACT

Vectorized small interfering RNAs (siRNAs) are widely used to induce gene silencing. Among the delivery systems used, lipid-based particles are the most effective. Our objective was the development of novel lipid-polymer hybrid nanoparticles, from lipoplexes (complexes of cationic lipid and siRNAs), and poly (lactic-co-glycolic acid) (PLGA), using a simple modified nanoprecipitation method. Due to their morphology, we called these hybrid nanoparticles Spheroplexes. We elucidated their structure using several physico-chemical techniques and showed that they are composed of a hydrophobic PLGA matrix, surrounded by a lipid envelope adopting a lamellar structure, in which the siRNA is complexed, and they retain surface characteristics identical to the starting nanoparticles, i.e. lipoplexes siRNA. We analyzed the composition of the particle population and determined the final percentage of spheroplexes within this population, 80 to 85% depending on the preparation conditions, using fluorescent markers and the ability of flow cytometry to detect nanometric particles (approximately 200 nm). Finally, we showed that spheroplexes are very stable particles and more efficient than siRNA lipoplexes for the delivery of siRNA to cultured cells. We administered spheroplexes contain siRNAs targeting TNF-α to mice with ulcerative colitis induced by dextran sulfate and our results indicate a disease regression effect with a response probably mediated by their uptake by macrophages / monocytes at the level of lamina propria of the colon. The efficacy of decreased level of TNF-α in vivo seemed to be an association of spheroplexes polymer-lipid composition and the specific siRNA. These results demonstrate that spheroplexes are a promising hybrid nanoparticle for the oral delivery of siRNA to the colon.


Subject(s)
Nanoparticles , Tumor Necrosis Factor-alpha , Animals , Cations/chemistry , Dextran Sulfate , Lipids/chemistry , Liposomes , Mice , Nanoparticles/chemistry , Polymers/chemistry , RNA, Small Interfering
3.
Int J Biol Macromol ; 169: 330-341, 2021 Feb 01.
Article in English | MEDLINE | ID: mdl-33310092

ABSTRACT

Vancomycin-loaded N,N-dodecyl,methyl-polyethylenimine nanoparticles coated with hyaluronic acid (VCM-DMPEI nanoparticles/HA) were synthesized as an adjuvant for the treatment of bacterial endophthalmitis. The nanoparticles were formulated by experimental statistical design, thoroughly characterized, and evaluated in terms of bactericidal activity and both in vitro and in vivo ocular biocompatibility. The VCM-DMPEI nanoparticles/HA were 154 ± 3 nm in diameter with a 0.197 ± 0.020 polydispersity index; had a + 26.4 ± 3.3 mV zeta potential; exhibited a 93% VCM encapsulation efficiency; and released 58% of the encapsulated VCM over 96 h. VCM and DMPEI exhibited a synergistic bactericidal effect. The VCM-DMPEI nanoparticles/HA were neither toxic to ARPE-19 cells nor irritating to the chorioallantoic membrane. Moreover, the VCM-DMPEI nanoparticles/HA did not induce modifications in retinal functions, as determined by electroretinography, and in the morphology of the ocular tissues. In conclusion, the VCM-DMPEI nanoparticles/HA may be a useful therapeutic adjuvant to treat bacterial endophthalmitis.


Subject(s)
Endophthalmitis/drug therapy , Polyethyleneimine/analogs & derivatives , Vancomycin/pharmacology , Anti-Bacterial Agents/pharmacology , Cell Line , Drug Carriers , Drug Liberation , Eye/drug effects , Humans , Hyaluronic Acid/metabolism , Hyaluronic Acid/pharmacology , Nanoparticles , Particle Size , Polyethyleneimine/chemistry , Polyethyleneimine/pharmacology , Vancomycin/chemistry
4.
Biomed Pharmacother ; 130: 110391, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32674015

ABSTRACT

PURPOSE: To evaluate the safety and potential healing efficacy of the topical ocular administration of a gelatin membrane containing usnic acid/liposomes (UALs) for corneal cicatrization. UALs have shown healing activity in animal models of dermal burn lesions. We evaluated the safety of topical ocular administration of UAL and its potential healing efficacy as an ophthalmic treatment on chemical lesions in rabbit eyes. METHOD: The Draize test was used to check for ocular toxicity and the score was zero at each observation, indicating the ocular safety of a gelatin membrane containing usnic acid/liposome. Its potential healing efficacy as an ophthalmic treatment on chemical lesions in rabbit eyes was also assessed. RESULTS: After epithelial removal and treatment with UAL, there was a 49.4 % reduction in injury under in vivo conditions compared with a 36.6 % reduction in the control, a gelatin membrane containing liposome without usnic acid. Histological analysis of ocular surface chemical injury-tissue sections after treatment with UAL supported these observations. The corneal expression of VEGF and TGF-ß1increased by 70 % and 50 % respectively following treatment with UAL gelatin membrane. CONCLUSION: These results indicate the potential therapeutic application of UAL gelatin membranes as an ophthalmic treatment that may be used for corneal cicatrization.


Subject(s)
Benzofurans/administration & dosage , Cicatrix/drug therapy , Cornea/drug effects , Drug Delivery Systems , Wound Healing/drug effects , Administration, Ophthalmic , Animals , Benzofurans/chemistry , Chickens , Cornea/blood supply , Female , Gelatin/administration & dosage , Gelatin/chemistry , Liposomes/administration & dosage , Liposomes/chemistry , Neovascularization, Physiologic/drug effects , Ophthalmic Solutions/chemistry
5.
Eur J Pharm Biopharm ; 142: 20-30, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31129274

ABSTRACT

Electrospinning technique has been explored to produce nanofibers incorporated with drugs as alternative drug delivery systems for therapeutic purposes in various organs and tissues. Before such systems could potentially be used, their biocompatibility must be evaluated. In this study, dexamethasone acetate-loaded poly(ɛ-caprolactone) nanofibers (DX PCL nanofibers) were developed for targeted delivery in the vitreous cavity in the treatment of retinal diseases. Ocular biocompatibility was tested in vitro and in vivo. DX PCL nanofibers were characterized by scanning electron microscopy (SEM) and Fourier Transform InfraRed spectroscopy (FTIR) and the in vitro drug release from nanofibers was evaluated. The in vitro biocompatibility of DX PCL nanofibers was tested on both ARPE-19 and MIO-M1 cells using the cytotoxicity (MTT) test by morphological studies based on staining of the actin fibers in ARPE-19 cells and GFAP in MIO-M1 cells. The in vivo biocompatibility of DX PCL nanofibers was investigated after intravitreous injection in the rat eye, using spectral domain Optical Coherence Tomography (OCT) imaging of the retina. SEM results indicated that nanometric fibers were interconnected in a complex network, and that they were composed of polymer. FTIR showed that polymer and drug did not chemically interact after the application of the electrospinning technique. PCL nanofibers provided controlled DX release for 10 days. DX PCL nanofibers were not cytotoxic to the ocular cells, allowing for the preservation of actin fibers and GFAP in the cytoplasm of ARPE-19 and MIO-M1 cells, respectively, which are biomarkers of these ocular cell populations. DX PCL nanofibers did not affect the retinal and choroidal structures, and they did not induce abnormalities, hemorrhages, or retinal detachment, suggesting that the nanofibers were well tolerated. In eyes receiving DX PCL nanofibers, SD-OCT images were corroborated with histological analysis of neuroretina and choroid, which are ocular tissues that are extremely sensitive to toxic agents. Finally, the preservation of cone and rod photoreceptors indicated the light sensitivity of the animals. In conclusion, DX PCL nanofibers exhibited ocular biocompatibility and safety in the rodent eye and allow the release of dexamethasone. Further studies are required to appreciate the potential of these new drug delivery systems for the treatment of retinal diseases.


Subject(s)
Dexamethasone/administration & dosage , Dexamethasone/chemistry , Nanofibers/administration & dosage , Nanofibers/chemistry , Polyesters/chemistry , Retina/drug effects , Animals , Cell Line , Cell Survival/drug effects , Drug Delivery Systems/methods , Drug Liberation/drug effects , Female , Humans , Rats , Rats, Inbred Lew , Retinal Diseases/drug therapy , Spectroscopy, Fourier Transform Infrared/methods , Tissue Engineering/methods , Tissue Scaffolds
6.
J Colloid Interface Sci ; 540: 342-353, 2019 Mar 22.
Article in English | MEDLINE | ID: mdl-30660791

ABSTRACT

Vectorized small interfering RNAs (siRNAs) are widely used to induce specific mRNA degradation in the intracellular compartment of eukaryotic cells. Recently, we developed efficient cationic lipid-based siRNA vectors (siRNA lipoplexes or siLex) containing sodium alginate (Nalg-siLex) with superior efficiency and stability properties than siLex. In this study, we assessed the physicochemical and some biological properties of Nalg-siLex compared to siLex. While no significant differences in size, ζ potential and siRNA compaction were detected, the addition of sodium alginate modified the particle morphology, producing smoother and heterogeneous particles characterized by transmission electron microscopy. We also noted that Nalg-siLex have surface differences observed by X-ray photoelectron spectroscopy. These differences could arise from an internal reorganization of components induced by the addition of sodium alginate, that is indicated by Small-Angle X-ray Scattering results. Moreover, Nalg-siLex did not trigger significant hepatotoxicity nor inflammatory cytokine secretion compared to siLex. Taken together these results suggest that sodium alginate played a key role by structuring and reinforcing siRNA lipoplexes, leading to more stable and efficient delivery vector.


Subject(s)
Alginates/chemistry , Gene Transfer Techniques , Liposomes/chemistry , RNA Interference , RNA, Small Interfering/administration & dosage , Animals , Cations/chemistry , Cell Line , Female , Lipids/chemistry , Mice, Inbred C57BL , Particle Size , RNA, Small Interfering/chemistry , RNA, Small Interfering/genetics , Static Electricity
8.
AAPS PharmSciTech ; 19(4): 1652-1661, 2018 May.
Article in English | MEDLINE | ID: mdl-29516291

ABSTRACT

Etoposide-loaded poly(lactic-co-glycolic acid) implants were developed for intravitreal application. Implants were prepared by a solvent-casting method and characterized in terms of content uniformity, morphology, drug-polymer interaction, stability, and sterility. In vitro drug release was investigated and the implant degradation was monitored by the percent of mass loss. Implants were inserted into the vitreous cavity of rabbits' eye and the in vivo etoposide release profile was determined. Clinical examination and the Hen Egg Test-Chorioallantoic Membrane (HET-CAM) method were performed to evaluate the implant tolerance. The original chemical structure of the etoposide was preserved after incorporation in the polymeric matrix, which the drug was dispersed uniformly. In vitro, implants promoted sustained release of the drug and approximately 57% of the etoposide was released in 50 days. In vivo, devices released approximately 63% of the loaded drug in 42 days. Ophthalmic examination and HET-CAM assay revealed no evidence of toxic effects of implants. These results tend to show that etoposide-loaded implants could be potentially useful as an intraocular etoposide delivery system in the future.


Subject(s)
Drug Implants/metabolism , Etoposide/metabolism , Lactic Acid/metabolism , Polyglycolic Acid/metabolism , Vitreous Body/metabolism , Animals , Chickens , Drug Implants/administration & dosage , Drug Implants/chemistry , Etoposide/administration & dosage , Etoposide/chemistry , Intravitreal Injections , Lactic Acid/administration & dosage , Lactic Acid/chemistry , Male , Polyglycolic Acid/administration & dosage , Polyglycolic Acid/chemistry , Polylactic Acid-Polyglycolic Acid Copolymer , Rabbits , Vitreous Body/drug effects
9.
Prog Retin Eye Res ; 63: 107-131, 2018 03.
Article in English | MEDLINE | ID: mdl-29097191

ABSTRACT

Retinitis Pigmentosa (RP) is a hereditary retinopathy that affects about 2.5 million people worldwide. It is characterized with progressive loss of rods and cones and causes severe visual dysfunction and eventual blindness in bilateral eyes. In addition to more than 3000 genetic mutations from about 70 genes, a wide genetic overlap with other types of retinal dystrophies has been reported with RP. This diversity of genetic pathophysiology makes treatment extremely challenging. Although therapeutic attempts have been made using various pharmacologic agents (neurotrophic factors, antioxidants, and anti-apoptotic agents), most are not targeted to the fundamental cause of RP, and their clinical efficacy has not been clearly proven. Current therapies for RP in ongoing or completed clinical trials include gene therapy, cell therapy, and retinal prostheses. Gene therapy, a strategy to correct the genetic defects using viral or non-viral vectors, has the potential to achieve definitive treatment by replacing or silencing a causative gene. Among many clinical trials of gene therapy for hereditary retinal diseases, a phase 3 clinical trial of voretigene neparvovec (AAV2-hRPE65v2, Luxturna) recently showed significant efficacy for RPE65-mediated inherited retinal dystrophy including Leber congenital amaurosis and RP. It is about to be approved as the first ocular gene therapy biologic product. Despite current limitations such as limited target genes and indicated patients, modest efficacy, and the invasive administration method, development in gene editing technology and novel gene delivery carriers make gene therapy a promising therapeutic modality for RP and other hereditary retinal dystrophies in the future.


Subject(s)
Genetic Therapy/methods , Retinitis Pigmentosa/genetics , Retinitis Pigmentosa/therapy , Biomedical Research , Clinical Studies as Topic , Humans , Molecular Biology
10.
Retina ; 35(2): 364-70, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25111686

ABSTRACT

PURPOSE: To investigate potential retinal neuroprotective effects of intravitreal triamcinolone acetonide and dexamethasone implant in rabbits after pars plana vitrectomy and intravitreal silicone oil injection. METHODS: The right eyes of 84 rabbits, divided into 3 groups of 28 rabbits each, underwent standard 3-port pars plana vitrectomy with silicone oil (SO group), silicone oil and intravitreal dexamethasone implant (SO/DEX group), or silicone oil and triamcinolone acetonide (SO/TA group). The retina from the left eye of each rabbit served as a control. The animals were killed at 4 weeks after surgery. Qualitative and quantitative histopathologic analyses were performed 4 weeks after surgery, and investigation for apoptosis was performed using the Tunel assay. RESULTS: Intravitreal triamcinolone acetonide and dexamethasone implant were associated with increased retinal neuronal survival, primarily in the outer nuclear layer, inner nuclear layer, and ganglion cell layer. In the SO group, the cell density in eyes that underwent PPV/SO was 31% lower in the outer nuclear layer, 33% lower in the inner nuclear layer, and 45% lower in the ganglion cell layer compared to control eyes (p < 0.05 for all PPV/SO versus control comparisons). Compared to eyes that underwent PPV/SO, the cell density in eyes treated with triamcinolone was 27% higher in the outer nuclear layer, 66% higher in the inner nuclear layer, and 100% higher in the ganglion cell layer (p < 0.05 for all triamcinolone versus PPV/SO comparisons). Compared to eyes that underwent PPV/SO, the cell density in eyes treated with dexamethasone was 46% higher in the outer nuclear layer, 62% higher in the inner nuclear layer, and 77% higher in the ganglion cell layer (p < 0.05 for all dexamethasone versus PPV/SO comparisons). Analyses using the Tunnel assay demonstrated apoptotic bodies in all eyes in the SO group, compared with none of the eyes in the SO/TA and SO/DEX groups. The presence of cell nuclei stained with 49,6-diamidino-2-phenylindole (DAPI) was demonstrated in all groups. CONCLUSION: In this experimental model of neuroprotection, increased retinal neuronal survival was seen in the steroid-treated groups compared with the controls.


Subject(s)
Dexamethasone/administration & dosage , Endotamponade , Glucocorticoids/pharmacology , Retina/drug effects , Silicone Oils/administration & dosage , Triamcinolone Acetonide/pharmacology , Vitrectomy , Animals , Apoptosis , Cell Count , Cell Survival , Drug Implants , In Situ Nick-End Labeling , Intravitreal Injections , Rabbits , Retinal Neurons/cytology , Retinal Neurons/drug effects , Retinal Neurons/physiology
11.
J Pharm Biomed Anal ; 84: 30-5, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23797039

ABSTRACT

Mycophenolic acid (MPA) is an immunosuppressive agent widely used in the treatment of solid organ transplant rejection. The success of MPA in the treatment of inflammatory intraocular diseases has been reported in recent literature. The treatment of inflammatory eye diseases in the posterior chamber is a challenge due to the anatomy of the eye, which presents certain barriers to drug access. Thus, the bioavailability of drugs in the eye is quite low, and successful drug delivery may well represent a key limiting factor to attaining a successful therapeutic strategy. Ophthalmic controlled drug delivery offers the potential to enhance the efficacy of treatment for pathological conditions. Thus, a novel delivery system based on a biodegradable polymeric device, which can be implanted inside the eye and deliver MPA directly to the target, is being developed. Specific analytical methods to determine the use of effective drugs within the eye are needed to characterize this device. A liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) method for the quantitation of MPA in the vitreous humor of rabbits was developed and validated. The vitreous was collected from rabbits, extracted by a protein precipitation extraction procedure and then separated on a C18 column with a mobile phase comprised of 0.15% aqueous acetic acid and methanol (60:40, v/v). The calibration curve was constructed within the range of 3-10,000 ng/mL for MPA. The mean R.S.D. values for the intra-run and inter-run precision were 5.15% and 4.35%. The mean accuracy value was 100.16%. The validated method was successfully applied to determine the MPA concentration in the vitreous humor of rabbits treated with an ocular implantable device.


Subject(s)
Chromatography, High Pressure Liquid/methods , Mycophenolic Acid/analysis , Mycophenolic Acid/pharmacokinetics , Spectrometry, Mass, Electrospray Ionization/methods , Tandem Mass Spectrometry/methods , Absorbable Implants , Animals , Drug Delivery Systems/methods , Female , Immunosuppressive Agents/chemistry , Immunosuppressive Agents/pharmacokinetics , Mycophenolic Acid/chemistry , Rabbits , Vitreous Body/chemistry , Vitreous Body/metabolism
12.
J Mater Sci Mater Med ; 24(5): 1309-17, 2013 May.
Article in English | MEDLINE | ID: mdl-23430334

ABSTRACT

The subretinal transplantation of retinal pigment epithelial cells (RPE cells) grown on polymeric supports may have interest in retinal diseases affecting RPE cells. In this study, montmorillonite based polyurethane nanocomposite (PU-NC) was investigated as substrate for human RPE cell growth (ARPE-19 cells). The ARPE-19 cells were seeded on the PU-NC, and cell viability, proliferation and differentiation were investigated. The results indicated that ARPE-19 cells attached, proliferated onto the PU-NC, and expressed occludin. The in vivo ocular biocompatibility of the PU-NC was assessed by using the HET-CAM; and through its implantation under the retina. The direct application of the nanocomposite onto the CAM did not compromise the vascular tissue in the CAM surface, suggesting no ocular irritancy of the PU-NC film. The nanocomposite did not elicit any inflammatory response when implanted into the eye of rats. The PU-NC may have potential application as a substrate for RPE cell transplantation.


Subject(s)
Bentonite/chemistry , Cell Proliferation , Polyurethanes/chemistry , Retinal Pigment Epithelium/physiology , Tissue Scaffolds , Aluminum Silicates/chemical synthesis , Aluminum Silicates/chemistry , Aluminum Silicates/pharmacology , Animals , Bentonite/pharmacology , Cell Proliferation/drug effects , Cells, Cultured , Chick Embryo , Clay , Female , Humans , Materials Testing , Nanocomposites/chemistry , Polyurethanes/chemical synthesis , Rats , Rats, Inbred BN , Retinal Pigment Epithelium/cytology , Retinal Pigment Epithelium/drug effects , Tissue Engineering/instrumentation , Tissue Engineering/methods , Tissue Scaffolds/chemistry
13.
J Pharm Biomed Anal ; 70: 544-8, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22673938

ABSTRACT

Ofloxacin, second-generation fluoroquinolone derivative, is one of the most commonly used to treat and prevent superficial ocular infection in animals and human beings. However, poor bioavailability, rapid elimination, and non compliance by patients are several problems associated with ocular route. Ophthalmic controlled drug delivery offers the potential to enhance the efficacy of treatment for pathological conditions, while reducing the side effects and the toxicity associated with frequent applications. Specific analytical methods to determine drugs in eye are needed to analyze and compare the new controlled release ocular devices with those conventional eye drops. The topical eye administration of ophthalmic drugs induces lachrymation, and the tear promotes a drug wash out. Quantify drugs in tear is a good tool to study their kinetic comportment in the eye. A liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) method for quantitation of ofloxacin in rabbits' tears was developed and validated. The tear was collected with tear strips, extracted by a liquid extraction procedure and then separated on an ACE C(18) column with a mobile phase composed of 0.15% aqueous formic acid and methanol (60:40, v/v). Calibration curve was constructed over the range of 10-5000 ng/mL for ofloxacin. The mean R.S.D. values for the intra-run and inter-run precision were 5.15% and 4.35%, respectively. The mean accuracy value was 100.16%. The validated method was successfully applied to determine the ofloxacin concentration in tears of rabbits treated with a mucoadhesive chitosan films and a conventional eye drop formulation.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Chitosan/chemistry , Chromatography, High Pressure Liquid , Ofloxacin/administration & dosage , Ofloxacin/pharmacokinetics , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry , Tears/metabolism , Adhesiveness , Administration, Ophthalmic , Animals , Anti-Bacterial Agents/chemistry , Calibration , Chemistry, Pharmaceutical , Chromatography, High Pressure Liquid/standards , Delayed-Action Preparations , Drug Carriers , Formates/chemistry , Limit of Detection , Male , Methanol/chemistry , Models, Animal , Ofloxacin/chemistry , Ophthalmic Solutions , Rabbits , Reference Standards , Reproducibility of Results , Sensitivity and Specificity , Spectrometry, Mass, Electrospray Ionization/standards , Tandem Mass Spectrometry/standards
14.
J Pharm Sci ; 100(7): 2886-95, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21283986

ABSTRACT

Implants are defined as controlled sustained release delivery systems of therapeutic agents incorporated or dispersed into a polymeric carrier. These systems can be implanted in specific organs and delivered by the therapeutic agents at the target site to treat various pathological processes. In the present study, the effects of dexamethasone-loaded polyurethane implants [PU ACT (dexamethasone acetate) implants] on inflammatory angiogenesis in a murine sponge model were investigated. PU ACT implants were inserted into nonbiocompatible sponges, used as a framework for fibrovascular tissue growth, and implanted into subcutaneous tissue located on the back of mice. After 7 days of implantation, the implant system was collected and processed for the assessment of hemoglobin (Hb; vascular index), myeloperoxidase (MPO), and N-acetyl-ß-D-glucosaminidase (NAG; inflammatory enzymes activities) and collagen content. ACT released from the polymeric implants provided a significant decrease in the neovascularization in the sponge (Hb content). PU ACT implants provided no effects on neutrophil infiltration (MPO activity) but macrophage recruitment was affected by the glucocorticoid delivered by implants (NAG activity). ACT released from implants was able to reduce the collagen deposition. The qualitative histological findings corroborated with the measured biochemical parameters. These local drug delivery systems derived from polyurethane efficiently modulated the key components of inflammation, angiogenesis, and fibrosis induced by sponge discs in an experimental animal model.


Subject(s)
Angiogenesis Inhibitors/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Dexamethasone/analogs & derivatives , Drug Carriers , Inflammation/prevention & control , Neovascularization, Pathologic/prevention & control , Polyurethanes/chemistry , Acetylglucosamine/metabolism , Angiogenesis Inhibitors/chemistry , Angiogenesis Inhibitors/pharmacokinetics , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacokinetics , Biomarkers/metabolism , Chemistry, Pharmaceutical , Collagen/metabolism , Dexamethasone/administration & dosage , Dexamethasone/chemistry , Dexamethasone/pharmacokinetics , Disease Models, Animal , Drug Compounding , Drug Implants , Female , Fibrosis , Hemoglobins/metabolism , Inflammation/etiology , Inflammation/metabolism , Inflammation/pathology , Macrophages/drug effects , Macrophages/enzymology , Mice , Neovascularization, Pathologic/etiology , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Neutrophils/drug effects , Neutrophils/enzymology , Peroxidase/metabolism , Surgical Sponges , Technology, Pharmaceutical/methods , Time Factors
15.
J Mater Sci Mater Med ; 20(2): 481-7, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18853235

ABSTRACT

Controlled delivery of drugs is a major issue in the treatment of ocular diseases, such as in the treatment of uveitis. In this study, dexamethasone acetate, an important type of corticoid used in the treatment of some uveitis, was incorporated into biodegradable polyurethanes (PU) having different macromolecular architectures. The biodegradable polyurethanes were obtained by preparing PU aqueous dispersions having poly(caprolactone) and/or poly(ethylene glycol) as soft segments. The drug was incorporated into the polymer by dissolving it in the PU aqueous dispersion. FTIR results showed the presence of the drug in the polymer with its original chemical structure. Small angle X-ray scattering (SAXS) results were explored to show that the incorporation of dexamethasone acetate led to the modification of the nanostructure of the polyurethane having only poly(caprolactone) as the soft segment, while the drug did not change significantly the microphase separated structure of PU having both poly(caprolactone) and poly(ethylene glycol) as soft segments. The evaluation of the release of the drug in vitro demonstrated that the obtained biodegradable polyurethanes were well succeeded in delivering dexamethasone acetate at an almost constant rate for 53 weeks. The presence of poly(ethylene glycol) together with poly(caprolactone) as soft segment in biodegradable PU was able to increase the rate of dexamethasone acetate release when compared to the rate of drug release from PU having only poly(caprolactone).


Subject(s)
Absorbable Implants , Delayed-Action Preparations/chemistry , Ophthalmic Solutions/administration & dosage , Ophthalmic Solutions/chemistry , Polyurethanes/chemistry , Biocompatible Materials/chemistry , Diffusion , Macromolecular Substances/chemistry , Materials Testing
16.
Drug Deliv ; 12(2): 109-16, 2005.
Article in English | MEDLINE | ID: mdl-15824036

ABSTRACT

Polylactic acid and polylactic-co-glycolic acid are biocompatible and biodegradable polymers with wide utility for the design of controlled release systems for drugs. Regarding intraocular application, polymeric sustained-drug release systems are being studied to treat vitreoretinal diseases. Our work aimed to compare the influence of two implant manufacturing techniques, compression and hot molding, on the in vitro degradation of the polymeric matrices and on the release of dexamethasone acetate. The results showed that the manufacturing technique highly influences degradation and drug release processes. The compressed systems degraded faster and allowed one faster release of the drug.


Subject(s)
Absorbable Implants , Drug Delivery Systems/methods , Eye , Delayed-Action Preparations/chemical synthesis , Delayed-Action Preparations/pharmacokinetics , Eye/drug effects , Eye/metabolism
17.
Clin Exp Ophthalmol ; 32(6): 626-32, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15575833

ABSTRACT

AIM: Eye drops are the most used dosage form by the ocular route, in spite of their low bioavailability. Due to their properties and numerous advantages, microemulsions are promising systems for topical ocular drug delivery. They can increase water solubility of the drug and enhance drug absorption into the eye. The present study describes the development and characterization of an oil-in-water microemulsion containing dexamethasone and the evaluation of its pharmacokinetics in rabbits after topical ocular application. METHODS: The microemulsion was prepared by the titration technique. Its physico-chemical characteristics and stability were determined. The ocular irritation test and the pharmacokinetics of this system were studied in white rabbits. RESULTS: The developed system showed an acceptable physico-chemical behaviour and presented good stability for 3 months. The ocular irritation test used suggested that the microemulsion did not provide significant alteration to eyelids, conjunctiva, cornea and iris. This formulation showed greater penetration of dexamethasone in the anterior segment of the eye and also release of the drug for a longer time when compared with a conventional preparation. The area under the curve obtained for the microemulsion system was more than twofold higher than that of the conventional preparation (P < 0.05). CONCLUSIONS: The microemulsion-based dexamethasone eye drop is advantageous for ophthalmic use because it is well-tolerated in the eye and seemed to provide a higher degree of bioavailability. The developed system shows greater penetration in the eye, allowing the possibility of decreasing the number of applications of eye drops per day.


Subject(s)
Dexamethasone/administration & dosage , Drug Delivery Systems , Glucocorticoids/administration & dosage , Administration, Topical , Animals , Anterior Eye Segment/metabolism , Area Under Curve , Benzalkonium Compounds/chemistry , Biological Availability , Dexamethasone/pharmacokinetics , Emulsions , Glucocorticoids/pharmacokinetics , Hydrogen-Ion Concentration , Myristates/chemistry , Ophthalmic Solutions , Pharmaceutical Preparations , Propylene Glycol/chemistry , Rabbits , Viscosity
SELECTION OF CITATIONS
SEARCH DETAIL
...